(Q35772604)

10 August 2017

1 reference

title

Genes differentially expressed in prostate cancer (English)

1 reference

10 August 2017

Eder IE

1

1 reference

10 August 2017

Bektic J

2

1 reference

10 August 2017

Haag P

3

1 reference

10 August 2017

Bartsch G

4

1 reference

10 August 2017

Klocker H

5

1 reference

10 August 2017

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

93

1 reference

10 August 2017

8

1 reference

10 August 2017

1151-1155

1 reference

Prostate cancer screening in the Tyrol, Austria: experience and results

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Molecular biology of the androgen receptor: from molecular understanding to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Her2 expression in prostatic cancer: a comparison with mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Age-Associated Changes in Histology and Gene-Expression Profile in the Rat Ventral Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

The program of androgen-responsive genes in neoplastic prostate epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Expression of NKX3.1 in normal and malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

New directions for ZD1839 in the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Growth factors and their receptors: new targets for prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Expression profiling using cDNA microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2004.04869.X

10.1111/J.1464-410X.2004.04869.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference